熱門資訊> 正文
iBio放弃了拟议的公开募股
2025-08-19 04:12
- iBio, Inc.(IBIO) 0
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- iBio (NASDAQ:IBIO) said on Monday that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares of iBio’s common stock, and (ii) accompanying Series G warrants and Series H warrants each representing the right to purchase a fraction of a share of iBio’s common stock.
- All of the securities to be sold in the proposed offering will be offered by iBio.
- iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes.
- iBio (NASDAQ:IBIO) shares were down more than 13% in extended trading.
More on iBio
- Seeking Alpha’s Quant Rating on iBio
- Historical earnings data for iBio
- Financial information for iBio
推薦文章
萬億南向「活水」瘋狂搶籌！重倉阿里巴巴逾1200億港元，如何抄「聰明錢」的作業？
「AI暴力美學」！一文盤點：「甲骨文之夜」留下的那些驚人數字
新股申購 | 「新葯開發公司」勁方醫藥-B今起招股！一手入場費4119.13港元
華盛早報 | 市值一夜暴增1.73萬億，新晉世界首富誕生；降息預期拉滿，特朗普怒噴鮑威爾
降息預期壓倒經濟隱憂！調查顯示：美股今年有望強勢收官
9月11日外盤頭條：特朗普誓要罷免美聯儲理事庫克 甲骨文暴漲36% 創始人盤中登頂首富 美勞工部預審查統計局
美股機會日報 | 美國8月PPI低於預期！三大股指期貨短線拉昇；甲骨文盤前飆升超30%
美聯儲下周要降息50基點？這八大降息交易方向值得關注！黃金已搶跑10%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
